Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland.  The pharmaceutical giant is spending $1 billion to expand an existing site in Limerick Ireland, to increase the production of certain active ingredients, including those used in its Alzheimer's treatment Kisunla.

Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer's drugs

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldwide INDIANAPOLIS , Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease.

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

Novo Nordisk

As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin.

2 Weight Loss Drug Stocks Worth Stashing Away for Years

Eli Lilly's experimental insulin that is injected just once a week is as effective as daily insulin injections for maintaining blood sugar levels in patients with type 1 or type 2 diabetes, researchers said on Tuesday at the European Association for the Study of Diabetes meeting in Madrid.

Health Rounds: Once-weekly insulin from Eli Lilly appears effective as daily injections

Eli Lilly has been an innovative force in medicine for a long time. The company is making waves for its progress in weight loss and Alzheimer's, but there is another big reason Lilly should be on your radar.

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound)

Regeneron Pharmaceuticals

These two drugmakers have been delivering significantly above-average returns for years. Both still have excellent prospects and could decide to split their stocks as their share prices get higher.

Prediction: These 2 Companies Will Split Their Stocks by 2027

Detailed results were published in The Lancet and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024 INDIANAPOLIS , Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 1 diabetes who require daily basal and multiple daily mealtime insulin injections.

With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes

In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7%  Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024 INDIANAPOLIS , Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 2 diabetes using insulin for the first time (insulin naïve).

Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes

Banco de Chile

Moody's

LLY, MCO, and BCH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 10, 2024.

Best Momentum Stocks to Buy for September 10th

Cool Co Ltd

LSI Industries

Zuora

CLCO, BCH, ZUO, LLY and LYTS have been added to the Zacks Rank #1 (Strong Buy) List on September 10, 2024.

New Strong Buy Stocks for September 10th

U.S. drugmaker Eli Lilly on Monday said it has appointed insider Lucas Montarce as its new chief financial officer, effective immediately, months after former CFO Anat Ashkenazi stepped down to join Google parent Alphabet.

Lilly appoints insider as finance chief amid rising investments to boost capacity

While reported use of Sanofi/Regeneron's Dupixent has declined with the adoption of LEO's Adbry, Pfizer's Cibinqo, and AbbVie's Rinvoq, the overall population receiving advanced treatments is on the rise, according to Spherix Global Insights. While reported use of Sanofi/Regeneron's Dupixent has declined with the adoption of LEO's Adbry, Pfizer's Cibinqo, and AbbVie's Rinvoq, the overall population receiving advanced treatments is on the rise, according to Spherix Global Insights.

The Highly Anticipated FDA Approvals of Galderma's Nemolizumab and Eli Lilly's Lebrikizumab are Expected to Shift Dermatologists' Perceptions of the Atopic Dermatitis Market

INDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately.

Lilly appoints Lucas Montarce as executive vice president and chief financial officer

Glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound have been multibillion-dollar hits for Lilly, and their growth could just be getting started. Lilly is about to enter the Alzheimer's market, an opportunity worth more than $30 billion where it has little in the way of competition.

This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth.

Eli Lilly has three likely blockbuster drugs that are relatively new to the market. Its pipeline features three other late-stage candidates with blockbuster potential.

Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly

MercadoLibre

Microsoft

Unless you have been living under the rock, you'd have heard of Nvidia's (NASDAQ: NVDA) success story.

Prediction: These 3 Stocks Will Outperform NVIDIA in 2025

argenx

Rhythm Pharmaceuticals

TG Therapeutics

Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.

Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals

When stocks rally, they tend to run into resistance if they reach a price level that had been resistance before. And sometimes, after hitting it they reverse and head lower.

Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed

Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the company said.

Health Rounds: Next generation Lilly weight-loss drug shows added heart, liver benefits

Eli Lilly's weight loss drugs are bringing in billions of dollars in revenue, and their performance even prompted the company to increase its annual revenue guidance. But one thing has limited the revenue potential of these drugs.

This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem

Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter continuous glucose monitor in U.S.

Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock

Eli Lilly and Company (NYSE:LLY ) Morgan Stanley 22nd Annual Global Healthcare Conference Call September 5, 2024 7:45 AM ET Company Participants Jacob Van Naarden - Executive Vice President & President of Lilly Oncology Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Good morning, everybody.

Eli Lilly and Company (LLY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Eli Lilly has entered into a research deal with artificial intelligence-focused firm Genetic Leap for up to $409 million to develop genetic medicines, the latter said on Thursday.

Eli Lilly signs research deal with AI-focused Genetic Leap

A pair of late-stage trials found that Eli Lilly's experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the company's race with Novo Nordisk to develop longer-acting insulins.

News for Eli Lilly Stock (LLY)